Key Takeaway
Largest meta-analysis on steps and mortality (226,889 participants) found every 1,000-step increase reduces all-cause mortality by 15%, with benefits starting at just 2,337 steps/day for cardiovascular mortality.
Summary
This meta-analysis pooled data from 17 cohort studies involving 226,889 participants with a median follow-up of 7.1 years, making it the largest study to date examining the dose-response relationship between daily step count and mortality.
The analysis found a significant nonlinear inverse association between daily steps and both all-cause and cardiovascular mortality. Each 1,000-step increment was associated with a 15% reduction in all-cause mortality risk, while each 500-step increment was associated with a 7% reduction in cardiovascular mortality risk. Benefits began at remarkably low thresholds: 3,867 steps/day for all-cause mortality and just 2,337 steps/day for cardiovascular mortality.
Subgroup analyses showed the relationship held across age groups, though the optimal number of steps differed. For those under 60, the biggest risk reduction occurred up to approximately 7,000-13,000 steps/day, while adults 60+ saw the greatest benefits up to 6,000-10,000 steps/day. There was no upper threshold at which more steps became harmful.
Methods
- Systematic review and meta-analysis of 17 prospective cohort studies
- 226,889 total participants, median follow-up 7.1 years
- Step counts measured by accelerometer or pedometer
- Restricted cubic splines used for dose-response modeling
- Subgroup analyses stratified by age (<60 vs. 60+), sex, and geography
- Adjusted for standard confounders
Key Results
- Each 1,000-step/day increase: 15% lower all-cause mortality (HR 0.85, 95% CI 0.81-0.91)
- Each 500-step/day increase: 7% lower cardiovascular mortality (HR 0.93, 95% CI 0.91-0.95)
- Benefits start at 3,867 steps/day for all-cause mortality
- Benefits start at 2,337 steps/day for cardiovascular mortality
- Adults <60: optimal range 7,000-13,000 steps/day
- Adults 60+: optimal range 6,000-10,000 steps/day
- No upper limit where additional steps increase risk
Limitations
- Observational design (cannot establish causation)
- Heterogeneity in step measurement devices across studies
- Single time-point step assessment in most cohorts
- Possible healthy user bias (healthier people walk more)
- Limited data on very high step counts (>15,000/day)